phase 1 clinical trial

phase 1 clinical trial

Phase 1 study. See Phase study.
References in periodicals archive ?
This year, the Phase 1 clinical trial in degenerative knee arthritis has been completed.
Exelixis' development pipeline includes: XL119, which has entered a Phase 3 clinical trial as a potential treatment for bile duct tumors; XL784, a compound that has completed a Phase 1 clinical trial; XL647, an anticancer compound that has entered a Phase 1 clinical trial; XL999, XL844, XL820 and XL880, anticancer compounds that are potential IND candidates; and multiple other compounds in preclinical development.
- US-based immuno-oncology company Arch Oncology, Inc has initiated a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed, the company said.
Wave Life Sciences announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy, or DMD, who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial.
In a Phase 1 clinical trial designed to test the safety of the therapy, the cells were introduced into 14 patients and were found to be safe.
Xenon announced final results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation, or TMS, studies, along with interim results from its XEN901 Phase 1 clinical trial, in posters at the American Epilepsy Society, or AES.
Dale Dhanoa, PhD, CEO of Akaal Pharma, said: "We are pleased with the results of our recently completed Phase 1 clinical trial in which our drug candidate AKP-11 has shown an excellent safety, tolerability and efficacy for treating psoriasis.
Aravive announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers.
Its previous placebo-controlled, Phase 1 clinical trial of HTX-011 in healthy volunteers achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam.
Dose escalation within the MAD portion of the Phase 1 clinical trial demonstrated that 600 mg of SPR994 provides greater drug exposure than was observed in the first dosing cohort of 300 mg while maintaining a favorable safety profile.
Omeros is hoping to launch a Phase 1 clinical trial evaluating OMS721 early in the third quarter.
Spero Therapeutics reported positive results from an interim analysis of its ongoing single ascending dose and multiple ascending dose Phase 1 clinical trial of SPR994, its investigational oral carbapenem product candidate designed for the treatment of Gram-negative infections, in healthy volunteers.